Filing Details
- Accession Number:
- 0001209191-11-042173
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2011-08-02 21:18:44
- Reporting Period:
- 2011-08-01
- Filing Date:
- 2011-08-02
- Accepted Time:
- 2011-08-02 21:18:44
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1103390 | Ardea Biosciences Inc. | RDEA | Pharmaceutical Preparations (2834) | 943200380 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1370348 | A Craig Johnson | 4939 Directors Place San Diego CA 92121 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2011-08-01 | 1,000 | $12.16 | 1,000 | No | 4 | M | Direct | |
Common Stock | Disposition | 2011-08-01 | 1,000 | $23.16 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2011-08-01 | 1,000 | $0.00 | 1,000 | $12.16 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
9,500 | 2019-01-01 | No | 4 | M | Direct |
Footnotes
- The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of March 24, 2011 and amended on June 23, 2011.
- The range of sales prices received was $23.06 to $23.34. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.
- Immediately exercisable, subject to a right of repurchase on behalf of the Issuer that lapsed one year from the grant date.